Timber Pharmaceuticals LLC, a startup created by New Jersey-based investment and operating firm Tardimed Sciences LLC, said it's poised to make a fresh leap into the public market this year with plans to take over Biopharmx Corp.'s NYSE listing in a new reverse merger deal.
The pending Abbvie Inc. merger with Allergan plc, expected to close in the first quarter, brought good tidings to another “A” company on Monday, allowing Astrazeneca plc to regain global rights to its late-stage Crohn’s disease and ulcerative colitis (UC) drug, brazikumab, an anti-IL-23 therapy that was out-licensed to Allergan in a $1.27 billion deal in 2016.
SANTA CLARA, Calif. – Diabetes seems likely to be the first area to really show concrete products and results for the ambitious Verily Life Sciences, which is the med-tech business of Mountain View, Calif.-based Google parent Alphabet Inc. However, its two major diabetes partners both have been rethinking the relationship.
HONG KONG - Singapore-based biotech Aum Biosciences Pte. Ltd., and Toronto, Canada-based biotech Cyclica Inc. have agreed to work together to apply Cyclica’s drug discovery platform in Aum’s R&D programs for the discovery of potential new cancer therapies. Aum will deploy its drug R&D skills including a biomarker-driven approach while Cyclica will contribute its AI-augmented platforms, Ligand Design and Ligand Express.
SAN FRANCISCO – Following years of mutual admiration, Germany's Biontech SE is moving to acquire Cambridge, Mass.-based Neon Therapeutics Inc., a neoantigen-based T-cell therapy specialist, in an all-stock transaction valued at about $67 million.
BEIJING – In a deal that adds another clinical-stage program to its pipeline, U.S.-China biotech Oncologie Inc. has picked up global rights to phase II-ready anti-DLL4/VEGF bispecific antibody navicixizumab from London-based Mereo Biopharma Group plc.
HONG KONG – In less than a year, China-based Shanghai Miracogen Inc. has extended its partnership with Oss, the Netherlands based Synaffix BV for a second antibody-drug conjugate (ADCs) candidate. The new deal is similar to one signed last year in that it gives Miracogen nonexclusive rights to Synaffix’s Glycoconnect and Hydraspace ADC technologies for use in a second clinical candidate.
HONG KONG – Global pharmaceutical company Mundipharma Pte Ltd. is gaining exclusive commercialization rights in Taiwan and Hong Kong to four biosimilar candidates from South Korean biopharma Samsung Bioepis Co. Ltd. targeting immunology and oncology.
Adaptimmune plc continued its bright start to the year by entering an alliance worth up to $897.5 million with Astellas Pharma Inc. to co-develop and co-commercialize stem cell-based allogeneic CAR T and T-cell receptor (TCR) cell therapies.
Pfizer Inc. was a swinging door today as it sold its small molecule for treating patients with behavioral and neurological symptoms to Biogen Inc., while licensing reboxetine’s data and intellectual property and granting esreboxetine’s development and commercialization rights to Axsome Therapeutics Inc.
RSS
